(Q36652058)

15 August 2017

1 reference

title

Mycophenolate mofetil in liver transplantation--is monotherapy safe? (English)

1 reference

15 August 2017

4

Peter Neuhaus

1 reference

15 August 2017

Maximilian Schmeding

1

1 reference

15 August 2017

Ulf P Neumann

series ordinal

2

1 reference

15 August 2017

Ruth Neuhaus

series ordinal

3

1 reference

15 August 2017

publication date

1 January 2006

1 reference

15 August 2017

published in

Clinical Transplantation

1 reference

15 August 2017

volume

20 Suppl 17

1 reference

15 August 2017

page(s)

75-79

1 reference

Mycophenolate mofetil combination therapy improves long-term outcomes after liver transplantation in patients with and without hepatitis C.

15 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-0012.2006.00604.X

Long-term efficacy and safety of mycophenolate mofetil in liver transplant recipients with calcineurin inhibitor-induced renal dysfunction

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-0012.2006.00604.X

Mycophenolatemofetil for immunosuppression after liver transplantation: a follow-up study of 191 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-0012.2006.00604.X

Effectiveness and safety of mycophenolate mofetil as monotherapy in liver transplantation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-0012.2006.00604.X

Mycophenolate mofetil can be used as monotherapy late after liver transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-0012.2006.00604.X

Monitoring mycophenolate in liver transplant recipients: toward a therapeutic range.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-0012.2006.00604.X

Replacement of calcineurin inhibitors with mycophenolate mofetil in liver-transplant patients with renal dysfunction: a randomised controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-0012.2006.00604.X

Mycophenolate mofetil monotherapy in liver transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-0012.2006.00604.X

Long-term mycophenolate mofetil monotherapy in combination with calcineurin inhibitors for chronic renal dysfunction after liver transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-0012.2006.00604.X

Mycophenolate mofetil monotherapy in liver transplant recipients: a single center experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-0012.2006.00604.X

Mycophenolate mofetil for renal dysfunction after pediatric liver transplantation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-0012.2006.00604.X

Mycophenolate mofetil for renal dysfunction in liver transplant recipients on cyclosporine or tacrolimus: randomized, prospective, multicenter pilot study results

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-0012.2006.00604.X

Mycophenolic Acid Pharmacodynamics and Pharmacokinetics Provide a Basis for Rational Monitoring Strategies

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-0012.2006.00604.X

Ribavirin and mycophenolic acid potentiate the activity of guanine- and diaminopurine-based nucleoside analogues against hepatitis B virus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-0012.2006.00604.X

Mycophenolic acid, an immunosuppressive agent, inhibits HBV replication in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-0012.2006.00604.X

MMF and calcineurin taper in recurrent hepatitis C after liver transplantation: impact on histological course

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-0012.2006.00604.X

10.1111/J.1399-0012.2006.00604.X

21 January 2018

Identifiers

DOI

1 reference

15 August 2017

1 reference